MB
NEO icon

MPM BioImpact’s NeoGenomics NEO Stock Holding History

MPM BioImpact’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-135,573
Closed -$1.1M – 39
2022
Q2 		$1.1M Hold
135,573
– – 0.31% 34
2022
Q1 		$1.65M Sell
135,573
-4,849
-3% -$102K 0.44% 34
2021
Q4 		$4.79M Sell
140,422
-9,082
-6% -$356K 0.87% 25
2021
Q3 		$7.21M Buy
+149,504
New +$6.92M 1.12% 21

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MPM BioImpact's NEO Position: Q3 2022 in Review

MPM BioImpact sold out of NeoGenomics (NEO) in Q3 2022, closing a stake of 135,573 shares — an estimated $1.1M sold.

MPM BioImpact first reported a position in NEO in Q3 2021 and held it in 4 quarters. The position peaked at $7.21M in Q3 2021. 245 funds tracked by Wall St. Rank hold NEO as of Q3 2022.

  • MPM BioImpact reported no remaining NeoGenomics position as of Q3 2022 after selling out during the quarter.
  • MPM BioImpact sold 135,573 NeoGenomics shares in Q3 2022, an estimated $1.1M.
  • MPM BioImpact first reported a position in NeoGenomics in Q3 2021 and held it in 4 quarters.
  • MPM BioImpact's NeoGenomics position peaked at $7.21M in Q3 2021.
  • 245 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2022.

Based on MPM BioImpact's 13F filing for Q3 2022, filed 14 Nov 2022.